Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 2
1972 1
1974 3
1975 1
1976 1
1977 9
1978 9
1979 3
1980 3
1981 3
1982 5
1983 4
1984 1
1985 2
1986 1
1987 3
1988 1
1989 1
1990 3
1991 2
1997 1
1998 3
1999 4
2000 1
2002 1
2003 1
2004 1
2005 3
2006 8
2007 5
2008 1
2009 3
2010 2
2011 2
2012 2
2013 4
2014 4
2015 3
2016 3
2017 5
2018 6
2019 5
2020 6
2021 5
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

134 results
Results by year
Filters applied: . Clear all
Page 1
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, Heijnen E, Condit R, Shukarev G, Heerwegh D, van Heesbeen R, Schuitemaker H, Douoguih M, Evans E, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Custers J, et al. Among authors: gurwith m. Vaccine. 2021 May 21;39(22):3081-3101. doi: 10.1016/j.vaccine.2020.09.018. Epub 2020 Oct 3. Vaccine. 2021. PMID: 33676782 Free PMC article. Review.
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
Munoz FM, Cramer JP, Dekker CL, Dudley MZ, Graham BS, Gurwith M, Law B, Perlman S, Polack FP, Spergel JM, Van Braeckel E, Ward BJ, Didierlaurent AM, Lambert PH; Brighton Collaboration Vaccine-associated Enhanced Disease Working Group. Munoz FM, et al. Among authors: gurwith m. Vaccine. 2021 May 21;39(22):3053-3066. doi: 10.1016/j.vaccine.2021.01.055. Epub 2021 Feb 23. Vaccine. 2021. PMID: 33637387 Free PMC article. Review.
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.
Matsuda K, Migueles SA, Huang J, Bolkhovitinov L, Stuccio S, Griesman T, Pullano AA, Kang BH, Ishida E, Zimmerman M, Kashyap N, Martins KM, Stadlbauer D, Pederson J, Patamawenu A, Wright N, Shofner T, Evans S, Liang CJ, Candia J, Biancotto A, Fantoni G, Poole A, Smith J, Alexander J, Gurwith M, Krammer F, Connors M. Matsuda K, et al. Among authors: gurwith m. J Clin Invest. 2021 Mar 1;131(5):e140794. doi: 10.1172/JCI140794. J Clin Invest. 2021. PMID: 33529172 Free PMC article. Clinical Trial.
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M. Levine MM, et al. Among authors: gurwith m. Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.
Europe's neglected infections of poverty.
Hotez PJ, Gurwith M. Hotez PJ, et al. Among authors: gurwith m. Int J Infect Dis. 2011 Sep;15(9):e611-9. doi: 10.1016/j.ijid.2011.05.006. Epub 2011 Jul 16. Int J Infect Dis. 2011. PMID: 21763173 Free article. Review.
Estimating cholera incidence with cross-sectional serology.
Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, Kabir A, Gurwith M, Weil AA, Harris JB, Calderwood SB, Ryan ET, Qadri F, Leung DT. Azman AS, et al. Among authors: gurwith m. Sci Transl Med. 2019 Feb 20;11(480):eaau6242. doi: 10.1126/scitranslmed.aau6242. Sci Transl Med. 2019. PMID: 30787170 Free PMC article.
LC16m8: an attenuated smallpox vaccine.
Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. Kenner J, et al. Among authors: gurwith m. Vaccine. 2006 Nov 17;24(47-48):7009-22. doi: 10.1016/j.vaccine.2006.03.087. Epub 2006 Apr 21. Vaccine. 2006. PMID: 17052815 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Kochhar S, Kim D, Excler JL, Condit RC, Robertson JS, Drew S, Whelan M, Wood D, Fast PE, Gurwith M, Klug B, Khuri-Bulos N, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Kochhar S, et al. Among authors: gurwith m. Vaccine. 2020 Jul 31;38(35):5734-5739. doi: 10.1016/j.vaccine.2020.06.044. Epub 2020 Jul 9. Vaccine. 2020. PMID: 32653276 Free PMC article. Review.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
Eldridge JH, Egan MA, Matassov D, Hamm S, Hermida L, Chen T, Tremblay M, Sciotto-Brown S, Xu R, Dimitrov A, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG). Eldridge JH, et al. Among authors: gurwith m. Vaccine. 2021 Sep 7;39(38):5436-5441. doi: 10.1016/j.vaccine.2021.07.030. Epub 2021 Aug 7. Vaccine. 2021. PMID: 34373117 Free article. Review.
134 results